PTC Therapeutics, Inc.: Leerink Partners assumes coverage with Outperform vs Market Perform rating; target price $98 vs $70
PTCT•Related News
Ashland to host Innovation Day webcast, spotlights technology platforms progress
ASH•
Lyell Immunopharma management to join Baird Global Healthcare Conference fireside chat
LYEL•
Asian refiners, awaiting word on Saudi shipments, expect tighter supply
XLE•
Northisle Copper and Gold joins MVIS Global Junior Gold Miners Index in GDXJ rebalance
GDXJ•
Psyence BioMed names John Thorne project lead at new Texas ibogaine unit TIRC
PBM•